UroGen Pharma
URGN
167 hedge funds and large institutions have $1.02B invested in UroGen Pharma in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 53 reducing their positions, and 24 closing their positions.
371% more call options, than puts
Call options by funds: $33.9M | Put options by funds: $7.2M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
17% more capital invested
Capital invested by funds: $879M → $1.02B (+$145M)
4% more funds holding
Funds holding: 161 → 167 (+6)
2% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 53
1.67% less ownership
Funds ownership: 95.05% → 93.38% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$29.5M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$24.4M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$17.5M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$17M |
| 5 |
SCM
Superstring Capital Management
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$63.7M |
| 2 |
Millennium Management
New York
|
-$18.4M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.1M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$11.5M |
| 5 |
JP Morgan Chase
New York
|
-$8.42M |
URGN Hedge Fund Activity: Q4 2025 in Review
167 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2025, worth a combined $1.02B — up 17% from $879M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new URGN positions and 24 closed out — a net gain of 6 holders — while 52 added to existing stakes and 53 trimmed.
The largest buyer was American Century Companies, opening a new position worth an estimated $29.5M. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $63.7M sold.
- 167 institutional investors held UroGen Pharma (URGN) as of Q4 2025, up from 161 in Q3 2025.
- Funds reported $1.02B of UroGen Pharma stock for Q4 2025, up 17% quarter-over-quarter.
- 30 funds opened new UroGen Pharma positions in Q4 2025 and 24 closed out, a net change of +6 holders.
- The largest UroGen Pharma buyer in Q4 2025 was American Century Companies, an estimated $29.5M added.
- The largest UroGen Pharma seller in Q4 2025 was Toronto Dominion Bank, an estimated $63.7M sold.
Based on aggregated 13F filings for Q4 2025.